Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 616 to 630 of 817 results for mental health

  1. Ruxolitinib cream for treating non-segmental vitiligo in people 12 years and over (TA1088)

    Evidence-based recommendations on ruxolitinib cream (Opzelura) for treating non-segmental vitiligo in people 12 years and over.

  2. Digital technologies to support self-management of COPD: early value assessment (HTG736)

    Early value assessment (EVA) guidance on digital technologies to support self-management of COPD.

  3. Compression products for treating venous leg ulcers: late-stage assessment (HTG758)

    Late-stage assessment (LSA) guidance on compression products for treating venous leg ulcers.

  4. Imlifidase for desensitisation treatment before kidney transplant in people with chronic kidney disease (TA809)

    Evidence-based recommendations on imlifidase (Idefirix) for desensitisation treatment before kidney transplant in people with chronic kidney disease.

  5. Familial breast cancer: classification, care and managing breast cancer and related risks in people with a family history of breast cancer (CG164)

    This guideline covers care for people with a family history of breast, ovarian or another related (prostate or pancreatic) cancer. It aims to improve the long-term health of these families by describing strategies to reduce the risk of and promote early detection of breast cancer (including genetic testing and mammography). It also includes advice on treatments (tamoxifen, raloxifene) and surgery (mastectomy).

  6. Urinary tract infection (recurrent): antimicrobial prescribing (NG112)

    This guideline sets out an antimicrobial prescribing strategy for preventing recurrent urinary tract infections in children, young people and adults who do not have a catheter. It aims to optimise antibiotic use and reduce antibiotic resistance.

  7. Dupilumab for treating severe asthma with type 2 inflammation (TA751)

    Evidence-based recommendations on dupilumab (Dupixent) for treating severe asthma with type 2 inflammation that is inadequately controlled in people 12 years and over.

  8. New sepsis guideline targets faster, tailored treatments to benefit patients

    Patients aged 16 or over with suspected sepsis will receive more tailored treatment under updated NICE guidance published today.

  9. Efgartigimod for treating antibody-positive generalised myasthenia gravis (TA1069)

    Evidence-based recommendations on efgartigimod (Vyvgart) for treating antibody-positive generalised myasthenia gravis in adults.

  10. Myeloma: diagnosis and management (NG35)

    This guideline covers the diagnosing and managing of myeloma (including smouldering myeloma and primary plasma cell leukaemia) in people aged 16 and over. It aims to improve care for people with myeloma by promoting the most effective tests and treatments for myeloma and its complications.

  11. Rimegepant for treating migraine (TA919)

    Evidence-based recommendations on rimegepant (Vydura) for the acute treatment of migraine in adults.

  12. Diabetes in pregnancy: management from preconception to the postnatal period (NG3)

    This guideline covers managing diabetes and its complications in women who are planning pregnancy or are already pregnant. It aims to improve the diagnosis of gestational diabetes and help women with diabetes to self-manage their blood glucose levels before and during pregnancy.

  13. Thousands more people with advanced bowel cancer to benefit as NICE approves bevacizumab biosimilars

    More than 7,000 people in England will now be able to access to a life-extending treatment for advanced bowel cancer.

  14. Ibrutinib for treating Waldenstrom's macroglobulinaemia (TA795)

    Evidence-based recommendations on ibrutinib (Imbruvica) for Waldenstrom’s macroglobulinaemia in adults who have had at least 1 previous therapy.

  15. Personal, social, health and economic education focusing on sex and relationships and alcohol education

    Discontinued Reference number: GID-PHG0